Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

This study has been completed.
Sponsor:
Collaborator:
AGO Study Group
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00567554
First received: December 4, 2007
Last updated: February 9, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2015
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):